Phathom Pharmaceuticals, Inc. (PHAT): Long-Term Debt
$209.09M
As of 2025-12-31
$164.59M
As of 2026-06-30
+30.0%
3-year compound annual growth
+34.8%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $209.09M | +3.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $201.41M | +46.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $137.84M | +44.7% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $95.26M | +6.2% | 2024-06-14, Balance as of period end |
| 2021-12-31 | $89.67M | +90.8% | 2022-03-01, Balance as of period end |
| 2020-12-31 | $46.99M | +106.3% | 2021-03-30, Balance as of period end |
| 2019-12-31 | $22.78M | n/a | 2020-03-19, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $209.09M | +3.8% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $291.77M | -1.4% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $22.68M | -66.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $48.25M | +24.7% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $130.44M | +4.6% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $99.00M | +106.3% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $125.00M | n/a |
Compare PHAT, MRVI, PBYI, AKBA side by side · Screen every company in Pharmaceutical Preparations ↗